Katharina U Kessel1, Anika Bluemke1, Hans R Schöler1,2, Holm Zaehres1,3, Peter Schlenke4, Isabel Dorn4. 1. Department of Cell and Developmental Biology, Max Planck Institute for Molecular Biomedicine, Münster, Germany. 2. Medical Faculty, Westphalian Wilhelms University Münster, Münster, Germany. 3. Department of Anatomy and Molecular Embryology, Medical Faculty, Ruhr-University Bochum, Bochum, Germany. 4. Medical University Graz; Department for Blood Group Serology and Transfusion Medicine, Graz, Austria.
Abstract
BACKGROUND: The ex vivo generation of human hematopoietic stem cells (HSCs) with long-term repopulating capacity and multi-lineage differentiation potential represents the holy grail of hematopoiesis research. In principle, human induced pluripotent stem cells (hiPSCs) provide the tool for both studying molecular mechanisms of hematopoietic development and the ex vivo production of 'true' HSCs for transplantation purposes and lineage-specific cells, e.g. red blood cells, for transfusion purposes. CD43-expressing cells have been reported as the first hematopoietic cells during development, but whether or not these possess multilineage differentiation and long-term engraftment potential is incompletely understood. METHODS: We performed ex vivo generation of hematopoietic cells from hiPSCs using an embryoid body(EB)-based, xeno-product-free differentiation protocol. We investigated the multilineage differentiation potential of different FACS-sorted CD43-expressing cell subsets by colony-forming assays in semisolid media. Further, erythroid differentiation was investigated in more detail using established protocols. RESULTS: By using CD43, we were able to measure hematopoietic induction efficiency during hiPSC-derived EB differentiation. Further, we determined CD43+ cells as the cell population of origin for in vitro erythropoiesis. Furthermore, colony formation demonstrates that the multipotent hematopoietic stem and progenitor cell fraction is particulary enriched in the CD43hi CD45+ population.
BACKGROUND: The ex vivo generation of human hematopoietic stem cells (HSCs) with long-term repopulating capacity and multi-lineage differentiation potential represents the holy grail of hematopoiesis research. In principle, human induced pluripotent stem cells (hiPSCs) provide the tool for both studying molecular mechanisms of hematopoietic development and the ex vivo production of 'true' HSCs for transplantation purposes and lineage-specific cells, e.g. red blood cells, for transfusion purposes. CD43-expressing cells have been reported as the first hematopoietic cells during development, but whether or not these possess multilineage differentiation and long-term engraftment potential is incompletely understood. METHODS: We performed ex vivo generation of hematopoietic cells from hiPSCs using an embryoid body(EB)-based, xeno-product-free differentiation protocol. We investigated the multilineage differentiation potential of different FACS-sorted CD43-expressing cell subsets by colony-forming assays in semisolid media. Further, erythroid differentiation was investigated in more detail using established protocols. RESULTS: By using CD43, we were able to measure hematopoietic induction efficiency during hiPSC-derived EB differentiation. Further, we determined CD43+ cells as the cell population of origin for in vitro erythropoiesis. Furthermore, colony formation demonstrates that the multipotent hematopoietic stem and progenitor cell fraction is particulary enriched in the CD43hi CD45+ population.
Authors: Isabel Dorn; Katharina Klich; Marcos J Arauzo-Bravo; Martina Radstaak; Simeon Santourlidis; Foued Ghanjati; Teja F Radke; Olympia E Psathaki; Gunnar Hargus; Jan Kramer; Martin Einhaus; Jeong Beom Kim; Gesine Kögler; Peter Wernet; Hans R Schöler; Peter Schlenke; Holm Zaehres Journal: Haematologica Date: 2014-10-17 Impact factor: 9.941
Authors: Giovanni Amabile; Robert S Welner; Cesar Nombela-Arrieta; Anna Morena D'Alise; Annalisa Di Ruscio; Alexander K Ebralidze; Yevgenya Kraytsberg; Min Ye; Olivier Kocher; Donna S Neuberg; Konstantin Khrapko; Leslie E Silberstein; Daniel G Tenen Journal: Blood Date: 2012-12-04 Impact factor: 22.113
Authors: Andrejs Ivanovs; Stanislav Rybtsov; Richard A Anderson; Marc L Turner; Alexander Medvinsky Journal: Stem Cell Reports Date: 2014-03-27 Impact factor: 7.765
Authors: Dorin-Mirel Popescu; Rachel A Botting; Emily Stephenson; Kile Green; Simone Webb; Laura Jardine; Emily F Calderbank; Krzysztof Polanski; Issac Goh; Mirjana Efremova; Meghan Acres; Daniel Maunder; Peter Vegh; Yorick Gitton; Jong-Eun Park; Roser Vento-Tormo; Zhichao Miao; David Dixon; Rachel Rowell; David McDonald; James Fletcher; Elizabeth Poyner; Gary Reynolds; Michael Mather; Corina Moldovan; Lira Mamanova; Frankie Greig; Matthew D Young; Kerstin B Meyer; Steven Lisgo; Jaume Bacardit; Andrew Fuller; Ben Millar; Barbara Innes; Susan Lindsay; Michael J T Stubbington; Monika S Kowalczyk; Bo Li; Orr Ashenberg; Marcin Tabaka; Danielle Dionne; Timothy L Tickle; Michal Slyper; Orit Rozenblatt-Rosen; Andrew Filby; Peter Carey; Alexandra-Chloé Villani; Anindita Roy; Aviv Regev; Alain Chédotal; Irene Roberts; Berthold Göttgens; Sam Behjati; Elisa Laurenti; Sarah A Teichmann; Muzlifah Haniffa Journal: Nature Date: 2019-10-09 Impact factor: 69.504
Authors: Bárbara C M F Paes; Luiza C J R Stabeli; Péricles N M Costa; Maristela Delgado Orellana; Simone Kashima; Dimas Tadeu Covas; Virgínia Picanço-Castro Journal: Hematol Transfus Cell Ther Date: 2020-03-06